Back to Report Store Home

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018

  • Published: Sep-2018
  • Report Code: GBIHC045IDB
  • Report Format: pdf


Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Depression and Anxiety Disorders Report Coverage

2.2 Post-Traumatic Stress Disorder (PTSD) – Overview

2.3 Obsessive-Compulsive Disorder – Overview

2.4 Depression – Overview

3 Therapeutics Development

3.1 Post-Traumatic Stress Disorder (PTSD)

3.2 Obsessive-Compulsive Disorder

3.3 Depression

4 Therapeutics Assessment

4.1 Post-Traumatic Stress Disorder (PTSD)

4.2 Obsessive-Compulsive Disorder

4.3 Depression

5 Companies Involved in Therapeutics Development

5.1 Post-Traumatic Stress Disorder (PTSD)

5.2 Obsessive-Compulsive Disorder

5.3 Depression

6 Dormant Projects

6.1 Post-Traumatic Stress Disorder (PTSD)

6.2 Obsessive-Compulsive Disorder

6.3 Depression

7 Discontinued Products

7.1 Post-Traumatic Stress Disorder (PTSD)

7.2 Obsessive-Compulsive Disorder

7.3 Depression

8 Product Development Milestones

8.1 Post-Traumatic Stress Disorder (PTSD)

8.2 Obsessive-Compulsive Disorder

8.3 Depression

9 Appendix

9.1 Methodology

9.2 Coverage

9.3 Secondary Research

9.4 Primary Research

9.5 Expert Panel Validation

9.6 Contact Us

9.7 Disclaimer

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments